Senti Biosciences, Inc. Form 8-K Filing Summary

Senti Biosciences, Inc. has entered into a First Amendment to Lease, reducing their leased premises from approximately 91,910 to 45,955 rentable square feet, effective September 1, 2025. This amendment also reduces the monthly base rent and the Company's proportionate share of operating expenses and taxes. In connection with this, the Company has amended its sublease agreement with GeneFab, LLC, aligning GeneFab's obligations with the Company's revised lease terms. A Landlord Consent Amendment was also executed, with the Company paying $1.0 million to the Landlord. Additionally, a letter agreement with GeneFab allows for rent to be satisfied through work or services performed by GeneFab for the Company, with provisions for a $2.0 million credit if the Landlord draws from the Company's letter of credit. The Landlord is entitled to draw $2.0 million from the Company's existing $2.76 million letter of credit as consideration for the rent reduction.